Shanghai Kaibao Pharmaceutical CO.,Ltd (300039.SZ)
CNY 5.88
(3.34%)
CNY 5.88
(3.34%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 375.33 Million CNY | 36.31% |
| 2022 | 257.9 Million CNY | 25.16% |
| 2021 | 203.65 Million CNY | 19.5% |
| 2020 | 172.93 Million CNY | -49.53% |
| 2019 | 349.29 Million CNY | -3.71% |
| 2018 | 326.32 Million CNY | 1.18% |
| 2017 | 381.44 Million CNY | -2.23% |
| 2016 | 381.24 Million CNY | -2.68% |
| 2015 | 388.26 Million CNY | -9.84% |
| 2014 | 452.93 Million CNY | 18.93% |
| 2013 | 362.76 Million CNY | 35.21% |
| 2012 | 313.65 Million CNY | 21.7% |
| 2011 | 220.02 Million CNY | 35.9% |
| 2010 | 160.18 Million CNY | 86.18% |
| 2009 | 88.93 Million CNY | 15.08% |
| 2008 | 75.21 Million CNY | 56.56% |
| 2007 | 46.82 Million CNY | 103.43% |
| 2006 | 23.02 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 105.8 Million CNY | 76.27% |
| 2024 Q2 | 50.52 Million CNY | -55.01% |
| 2024 Q1 | 103.03 Million CNY | -30.76% |
| 2023 Q1 | 90.23 Million CNY | -24.54% |
| 2023 Q4 | 141.15 Million CNY | 156.3% |
| 2023 FY | - CNY | 36.31% |
| 2023 Q3 | 55.07 Million CNY | 7.26% |
| 2023 Q2 | 51.34 Million CNY | -43.1% |
| 2022 Q4 | 119.57 Million CNY | 417.22% |
| 2022 Q1 | 73.78 Million CNY | 52.53% |
| 2022 Q2 | 27.16 Million CNY | -63.19% |
| 2022 Q3 | 23.11 Million CNY | -14.88% |
| 2022 FY | - CNY | 25.16% |
| 2021 FY | - CNY | 19.5% |
| 2021 Q4 | 48.37 Million CNY | 25.19% |
| 2021 Q1 | 75.02 Million CNY | 94.2% |
| 2021 Q3 | 38.63 Million CNY | 60.32% |
| 2021 Q2 | 24.1 Million CNY | -67.87% |
| 2020 Q2 | 26.18 Million CNY | -59.0% |
| 2020 FY | - CNY | -49.53% |
| 2020 Q4 | 38.63 Million CNY | 40.37% |
| 2020 Q3 | 27.52 Million CNY | 5.11% |
| 2020 Q1 | 63.85 Million CNY | -37.49% |
| 2019 FY | - CNY | -3.71% |
| 2019 Q4 | 102.15 Million CNY | 109.62% |
| 2019 Q3 | 48.73 Million CNY | -52.15% |
| 2019 Q2 | 101.83 Million CNY | 30.76% |
| 2019 Q1 | 77.87 Million CNY | 31.27% |
| 2018 Q3 | 53.81 Million CNY | -49.09% |
| 2018 FY | - CNY | 1.18% |
| 2018 Q4 | 59.32 Million CNY | 10.24% |
| 2018 Q1 | 118.34 Million CNY | 715.29% |
| 2018 Q2 | 105.69 Million CNY | -10.69% |
| 2017 Q1 | 112.65 Million CNY | 178.13% |
| 2017 Q3 | 70.89 Million CNY | -44.42% |
| 2017 Q4 | 14.51 Million CNY | -79.52% |
| 2017 FY | - CNY | -2.23% |
| 2017 Q2 | 127.54 Million CNY | 13.22% |
| 2016 Q1 | 103.42 Million CNY | 68.86% |
| 2016 Q3 | 73.84 Million CNY | -39.34% |
| 2016 Q4 | 40.5 Million CNY | -45.15% |
| 2016 FY | - CNY | -2.68% |
| 2016 Q2 | 121.74 Million CNY | 17.71% |
| 2015 FY | - CNY | -9.84% |
| 2015 Q4 | 61.24 Million CNY | -3.36% |
| 2015 Q3 | 63.37 Million CNY | -44.07% |
| 2015 Q2 | 113.31 Million CNY | -2.83% |
| 2015 Q1 | 116.61 Million CNY | 27.21% |
| 2014 Q4 | 91.66 Million CNY | -5.29% |
| 2014 Q3 | 96.78 Million CNY | -13.78% |
| 2014 Q2 | 112.26 Million CNY | 14.98% |
| 2014 FY | - CNY | 18.93% |
| 2014 Q1 | 97.63 Million CNY | 55.88% |
| 2013 Q1 | 75.89 Million CNY | 34.69% |
| 2013 FY | - CNY | 35.21% |
| 2013 Q4 | 62.63 Million CNY | -34.95% |
| 2013 Q3 | 96.28 Million CNY | -6.16% |
| 2013 Q2 | 102.61 Million CNY | 35.2% |
| 2012 Q1 | 55.7 Million CNY | -24.28% |
| 2012 Q2 | 90 Million CNY | 61.57% |
| 2012 Q3 | 69.87 Million CNY | -22.37% |
| 2012 Q4 | 56.35 Million CNY | -19.35% |
| 2012 FY | - CNY | 21.7% |
| 2011 Q2 | 63.02 Million CNY | 62.34% |
| 2011 FY | - CNY | 35.9% |
| 2011 Q4 | 73.57 Million CNY | 57.12% |
| 2011 Q1 | 38.82 Million CNY | -30.28% |
| 2011 Q3 | 46.82 Million CNY | -25.7% |
| 2010 Q1 | 19.04 Million CNY | -18.46% |
| 2010 Q4 | 55.68 Million CNY | 14.3% |
| 2010 Q3 | 48.71 Million CNY | 8.64% |
| 2010 FY | - CNY | 86.18% |
| 2010 Q2 | 44.84 Million CNY | 135.49% |
| 2009 Q3 | 20.26 Million CNY | 8.58% |
| 2009 Q4 | 23.35 Million CNY | 15.23% |
| 2009 FY | - CNY | 15.08% |
| 2009 Q2 | 18.66 Million CNY | -3.52% |
| 2009 Q1 | 19.34 Million CNY | -23.19% |
| 2008 Q4 | 25.18 Million CNY | 134.68% |
| 2008 FY | - CNY | 56.56% |
| 2008 Q3 | 10.73 Million CNY | 0.0% |
| 2007 FY | - CNY | 103.43% |
| 2006 FY | - CNY | 0.0% |